- Top Celgene executives will collect 2.5X their salary and bonus in cash if they leave after the deal with BMS closes.
- A new severance agreement was formalized days ahead of the buyout press releases.
- CEO Mark Alles will get three times his salary when he leaves.
KEY TAKEAWAY: A report found that 27 percent of cancer survivors or close relatives of a cancer patient said they’d skipped doctor visits or taken other steps to reduce health costs. Yet, according to Fierce Pharma “defying critics in Congress and elsewhere, Celgene hiked the list prices of key cancer meds Revlimid and Pomalyst by 9% this month, taking their cumulative increases for the year to nearly double the range that many Big Pharma peers have pledged to avoid”.